Beta cell mass in diabetes: a realistic therapeutic target?
Beta cell deficiency underlies both type 1 and type 2 diabetes, and restoration or replacement of beta cell function is therefore the logical long-term solution to therapy. This review sets out to describe the defects in beta cell mass and function in both forms of diabetes, summarises current understanding of the underlying causes of beta cell death, and the methodological limitations of determining beta cell mass in vivo. Finally, the potential effects of current and future treatment regimens on beta cell mass and turnover are considered.
Meier
J J
JJ
Department of Medicine I, St Josef-Hospital, Ruhr-University of Bochum, Gudrunstr. 56, 44791, Bochum, Germany. juris.meier@rub.de
D017209:Apoptosis; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D012038:Regeneration
D007004:Hypoglycemic Agents